发明申请
- 专利标题： TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE
- 专利标题（中）： 截短的GLP-1衍生物及其治疗用途
-
申请号： US12676453申请日： 2008-09-05
-
公开(公告)号： US20100292133A1公开(公告)日： 2010-11-18
- 发明人: Jane Spetzler , Lauge Schäffer , Jesper Lau , János Tibor Kodra , Kjeld Madsen , Patrick William Garibay , Jacob Kofoed , Steffen Reedtz-Runge , Henning Thøgersen , Igrid Pettersson
- 申请人： Jane Spetzler , Lauge Schäffer , Jesper Lau , János Tibor Kodra , Kjeld Madsen , Patrick William Garibay , Jacob Kofoed , Steffen Reedtz-Runge , Henning Thøgersen , Igrid Pettersson
- 申请人地址： DK Bagsvard
- 专利权人： Novo Nordisk A/S
- 当前专利权人： Novo Nordisk A/S
- 当前专利权人地址： DK Bagsvard
- 优先权： EP07115743.2 20070905; EP08101010.0 20080128
- 国际申请： PCT/EP2008/061833 WO 20080905
- 主分类号： C07K14/605
- IPC分类号： C07K14/605 ; A61K38/26 ; A61P3/10 ; A61P3/00 ; A61P3/06 ; A61P3/08 ; A61P9/10 ; A61P9/00
摘要：
The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration.
信息查询
